Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Munn

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Tryptophan catabolism and regulation of adaptive immunityAndrew L Mellor, David H Munn
Immunological Reviews|September 16, 2006
The tumor-draining lymph node as an immune-privileged siteDavid H Munn, Andrew L Mellor
Trends in Molecular Medicine|January 15, 2004
IDO and tolerance to tumorsDavid H Munn, Andrew L Mellor
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Physiologic control of the functional status of Foxp3+ regulatory T cellsAndrew L Mellor, David H Munn
The Journal of Clinical Investigation|May 4, 2007
Indoleamine 2,3-dioxygenase and tumor-induced toleranceDavid H Munn, Andrew L Mellor
Nature Reviews. Immunology|October 2, 2004
IDO expression by dendritic cells: tolerance and tryptophan catabolismAndrew L Mellor, David H Munn
Trends in Immunology|October 30, 2012
Indoleamine 2,3 dioxygenase and metabolic control of immune responsesDavid H Munn, Andrew L Mellor
Current Pharmaceutical Design|February 7, 2003
Macrophages and the regulation of self-reactive T cellsDavid H Munn, Andrew L Mellor
Advances in Experimental Medicine and Biology|December 25, 2017
Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor MicroenvironmentTheodore S Johnson, Tracy Mcgaha, David H Munn
Oncoimmunology|January 23, 2015
Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulationZhi-Chun Ding, David H Munn, Gang Zhou
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Tryptophan catabolism and regulation of adaptive immunityAndrew L Mellor, David H Munn
Immunological Reviews|September 16, 2006
The tumor-draining lymph node as an immune-privileged siteDavid H Munn, Andrew L Mellor
Trends in Molecular Medicine|January 15, 2004
IDO and tolerance to tumorsDavid H Munn, Andrew L Mellor
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2011
Physiologic control of the functional status of Foxp3+ regulatory T cellsAndrew L Mellor, David H Munn
The Journal of Clinical Investigation|May 4, 2007
Indoleamine 2,3-dioxygenase and tumor-induced toleranceDavid H Munn, Andrew L Mellor
Nature Reviews. Immunology|October 2, 2004
IDO expression by dendritic cells: tolerance and tryptophan catabolismAndrew L Mellor, David H Munn
Trends in Immunology|October 30, 2012
Indoleamine 2,3 dioxygenase and metabolic control of immune responsesDavid H Munn, Andrew L Mellor
Current Pharmaceutical Design|February 7, 2003
Macrophages and the regulation of self-reactive T cellsDavid H Munn, Andrew L Mellor
Advances in Experimental Medicine and Biology|December 25, 2017
Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor MicroenvironmentTheodore S Johnson, Tracy Mcgaha, David H Munn
Oncoimmunology|January 23, 2015
Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulationZhi-Chun Ding, David H Munn, Gang Zhou
Pageof 15